Last reviewed · How we verify
TMC278; Moxifloxacin; Efavirenz
TMC278; Moxifloxacin; Efavirenz is a Small molecule drug developed by Tibotec Pharmaceuticals, Ireland. It is currently in Phase 1 development.
At a glance
| Generic name | TMC278; Moxifloxacin; Efavirenz |
|---|---|
| Sponsor | Tibotec Pharmaceuticals, Ireland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC278; Moxifloxacin; Efavirenz CI brief — competitive landscape report
- TMC278; Moxifloxacin; Efavirenz updates RSS · CI watch RSS
- Tibotec Pharmaceuticals, Ireland portfolio CI
Frequently asked questions about TMC278; Moxifloxacin; Efavirenz
What is TMC278; Moxifloxacin; Efavirenz?
TMC278; Moxifloxacin; Efavirenz is a Small molecule drug developed by Tibotec Pharmaceuticals, Ireland.
Who makes TMC278; Moxifloxacin; Efavirenz?
TMC278; Moxifloxacin; Efavirenz is developed by Tibotec Pharmaceuticals, Ireland (see full Tibotec Pharmaceuticals, Ireland pipeline at /company/tibotec-pharmaceuticals-ireland).
What development phase is TMC278; Moxifloxacin; Efavirenz in?
TMC278; Moxifloxacin; Efavirenz is in Phase 1.